Abstract: A vessel has an inner flap and an outer flap that fold across a base of the vessel to form a cover. The inner flap includes a dam tab along the outer edge of the inner flap. When the inner flap is folded down, the free edge of this tab contacts the wall of the vessel and bends upward forming a “folded edge” dam. This folded edge dam can either be one segment or be made of two or more segments divided by one or more V-shaped cuts to allow each segment to fold down and fit together seamlessly. A restrictive channel is formed by the outer and inner flaps together with the “folded edge” dam, which is present in-between the outer and inner flaps.

Abstract: A vessel has an inner flap and an outer flap that fold across a base of the vessel to form a cover. The inner flap includes a dam tab along the outer edge of the inner flap. When the inner flap is folded down, the free edge of this tab contacts the wall of the vessel and bends upward forming a “folded edge” dam. This folded edge dam can either be one segment or be made of two or more segments divided by one or more V-shaped cuts to allow each segment to fold down and fit together seamlessly. A restrictive channel is formed by the outer and inner flaps together with the “folded edge” dam, which is present in-between the outer and inner flaps.

Abstract: A vessel has an inner flap and an outer flap that fold across a base of the vessel to form a cover. The inner flap includes a dam tab along the outer edge of the inner flap. When the inner flap is folded down, the free edge of this tab contacts the wall of the vessel and bends upward forming a “folded edge” dam. This folded edge dam can either be one segment or be made of two or more segments divided by one or more V-shaped cuts to allow each segment to fold down and fit together seamlessly. A restrictive channel is formed by the outer and inner flaps together with the “folded edge” dam, which is present in-between the outer and inner flaps.

Abstract: A vessel has an inner flap and an outer flap that fold across a base of the vessel to form a cover. The inner flap includes a dam tab along the outer edge of the inner flap. When the inner flap is folded down, the free edge of this tab contacts the wall of the vessel and bends upward forming a “folded edge” dam. This folded edge dam can either be one segment or be made of two or more segments divided by one or more V-shaped cuts to allow each segment to fold down and fit together seamlessly. A restrictive channel is formed by the outer and inner flaps together with the “folded edge” dam, which is present in-between the outer and inner flaps.

Abstract: A vessel has an inner flap and an outer flap that fold across a base of the vessel to form a cover. The inner flap includes a dam tab along the outer edge of the inner flap. When the inner flap is folded down, the free edge of this tab contacts the wall of the vessel and bends upward forming a “folded edge” dam. This folded edge dam can either be one segment or be made of two or more segments divided by one or more V-shaped cuts to allow each segment to fold down and fit together seamlessly. A restrictive channel is formed by the outer and inner flaps together with the “folded edge” dam, which is present in-between the outer and inner flaps.

Abstract: The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(?)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

Abstract: The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(?)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.

Abstract: The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(?)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Abstract: The present invention is based on the discovery that protective antigen related molecules (PARMs) without anthrax lethal factor have antiangiogenic or anticancer properties. The invention is directed to a method of inhibiting an angiogenic disease/disorder or cancer. Additionally, the invention can be applied to those at risk for developing cancer or an angiogenic disease/disorder comprising administering to a mammal an angiogenesis-inhibiting or cancer inhibiting amount of an PARM (including analogs, or derivative thereof having angiogenesis-inhibiting or anticancer activity, consisting of PA, PA fragment, analog, or derivative that is administered in a composition substantially free of anthrax lethal factor or other toxins).

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(?)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

Abstract: A method of inhibiting neovascularization in a mammal comprises administering to the mammal a neovascularization-inhibiting amount of a compound of the formula disclosed.

Abstract: The invention provides new and useful analogs of 3-amino-thalidomide. These analogs include S(−)-3-amino-thalidomide and R(+)-3-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.